StocksFundsScreenerSectorsWatchlists
PSNL

PSNL - Personalis Inc Stock Price, Fair Value and News

1.26USD-0.01 (-0.79%)Market Closed

Market Summary

PSNL
USD1.26-0.01
Market Closed
-0.79%

PSNL Stock Price

View Fullscreen

PSNL RSI Chart

PSNL Valuation

Market Cap

63.6M

Price/Earnings (Trailing)

-0.59

Price/Sales (Trailing)

0.87

EV/EBITDA

-0.07

Price/Free Cashflow

-0.95

PSNL Price/Sales (Trailing)

PSNL Profitability

Operating Margin

24.78%

EBT Margin

-147.27%

Return on Equity

-83.66%

Return on Assets

-48.11%

Free Cashflow Yield

-105.55%

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

73.5M

Rev. Growth (Yr)

17.66%

Rev. Growth (Qtr)

7.83%

PSNL Earnings

Earnings (TTM)

-108.3M

Earnings Growth (Yr)

14.43%

Earnings Growth (Qtr)

8.64%

Breaking Down PSNL Revenue

Last 7 days

-10.6%

Last 30 days

-21.7%

Last 90 days

-23.6%

Trailing 12 Months

-58.8%

How does PSNL drawdown profile look like?

PSNL Financial Health

Current Ratio

3.11

PSNL Investor Care

Shares Dilution (1Y)

8.06%

Diluted EPS (TTM)

-2.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202368.7M67.1M70.5M73.5M
202279.8M76.4M69.0M65.0M
202180.4M82.5M85.0M85.5M
202070.3M74.0M76.6M78.6M
201947.7M54.7M60.2M65.2M
201816.5M23.6M30.7M37.8M
20170009.4M

Tracking the Latest Insider Buys and Sells of Personalis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 01, 2024
myers woodrow a jr
bought
16,700
1.67
10,000
-
Jan 29, 2024
chen richard
sold
-720
1.37
-526
chief medical officer and evp
Jan 29, 2024
tachibana aaron
sold
-980
1.37
-716
cfo and coo
Dec 15, 2023
tachibana aaron
sold
-9,918
1.47
-6,747
cfo and coo
Dec 15, 2023
moore stephen michael
sold
-2,169
1.47
-1,476
general counsel
Dec 15, 2023
chen richard
sold
-6,920
1.47
-4,708
chief medical officer and evp
Nov 16, 2023
chen richard
sold
-977
1.04
-940
chief medical officer and evp
Nov 16, 2023
tachibana aaron
sold
-1,397
1.04
-1,344
cfo and coo
Nov 16, 2023
moore stephen michael
sold
-1,790
1.04
-1,722
general counsel
Nov 01, 2023
hall christopher m
sold
-19,026
0.93
-20,459
president and ceo

1–10 of 50

Which funds bought or sold PSNL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Banque Cantonale Vaudoise
added
50.00
1,000
22,000
-%
Apr 10, 2024
Green Alpha Advisors, LLC
reduced
-0.3
-73,300
177,240
0.13%
Mar 11, 2024
VANGUARD GROUP INC
added
0.22
1,847,820
4,347,200
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
319
340,763
394,984
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-22,000
-
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
188
665,000
831,000
0.07%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
54,000
127,000
-%
Feb 15, 2024
BARCLAYS PLC
unchanged
-
41,000
95,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
40,824
40,824
-%
Feb 14, 2024
STATE STREET CORP
unchanged
-
115,915
273,508
-%

1–10 of 48

Are Funds Buying or Selling PSNL?

Are funds buying PSNL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PSNL
No. of Funds

Unveiling Personalis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 29, 2024
ark investment management llc
13.61%
6,671,545
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
3,315,268
SC 13G/A
Dec 07, 2023
jpmorgan chase & co
0.0%
0
SC 13G/A
Dec 05, 2023
tempus labs, inc.
15.8%
9,218,800
SC 13G
Feb 10, 2023
ark investment management llc
11.96%
5,500,400
SC 13G/A
Jan 31, 2023
blackrock inc.
7.7%
3,558,913
SC 13G/A
Jan 25, 2023
jpmorgan chase & co
7.6%
3,502,353
SC 13G/A
Mar 09, 2022
blackrock inc.
10.0%
4,502,224
SC 13G/A
Mar 07, 2022
lightspeed venture partners viii lp
9.16%
4,117,768
SC 13D/A
Feb 09, 2022
ark investment management llc
10.91%
4,888,115
SC 13G/A

Recent SEC filings of Personalis Inc

View All Filings
Date Filed Form Type Document
Apr 02, 2024
ARS
ARS
Apr 02, 2024
DEF 14A
DEF 14A
Apr 02, 2024
DEFA14A
DEFA14A
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Feb 29, 2024
S-8
Employee Benefits Plan
Feb 28, 2024
10-K
Annual Report

Peers (Alternatives to Personalis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.3B
23.9B
-3.91% -4.78%
37.37
7.42
-10.33% -33.23%
41.1B
6.7B
-4.92% 0.73%
33.25
6.1
-2.81% -6.58%
40.8B
3.7B
-7.22% 1.87%
48.33
11.16
8.72% 24.44%
14.2B
9.3B
0.30% -9.60%
16.68
1.54
-6.38% -9.73%
12.1B
4.1B
-8.95% 15.76%
25.51
2.93
3.86% -2.39%
11.9B
1.9B
-2.43% 101.48%
42.11
6.31
29.17% 15.26%
11.9B
2.5B
13.24% -2.16%
-58.11
4.75
19.93% 67.26%
10.9B
1.1B
0.99% 75.89%
-25.11
10.08
31.99% 20.63%
MID-CAP
2.6B
929.2M
-20.88% -25.40%
1.7K
2.8
28.93% 111.61%
2.1B
563.9M
-3.78% -30.33%
-4.33
3.68
25.45% 26.76%
SMALL-CAP
425.1M
280.3M
-19.03% -7.55%
-2.23
1.52
-12.89% -148.37%
86.5M
31.2M
4.27% -86.20%
-0.98
2.77
5.03% -1.81%
41.5M
9.2M
-6.67% -36.96%
-2.48
4.53
11.85% 44.12%
6.1M
9.0M
-2.70% -65.71%
-0.85
0.68
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Personalis Inc News

Latest updates
Defense World13 Apr 202410:20 am
Markets Insider06 Mar 202408:00 am
Yahoo Finance29 Feb 202408:00 am

Personalis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue7.8%19,675,00018,247,00016,699,00018,860,00016,722,00014,858,00018,240,00015,227,00020,682,00022,261,00021,670,00020,881,00020,176,00019,816,00019,495,00019,161,00018,154,00017,153,00015,825,00014,075,00013,157,000
Cost Of Revenue-2.0%14,470,00014,766,00011,907,00014,130,00014,410,00012,379,00013,959,00010,949,00012,686,00014,195,00013,502,00013,454,00014,106,00014,483,00014,823,00015,122,00011,589,00011,524,0009,923,00010,091,0008,328,000
Costs and Expenses-11.0%43,647,00049,040,00042,045,00048,685,00048,807,00042,117,00046,121,00043,533,00040,907,00039,952,00036,617,00033,371,00033,546,00029,469,00028,993,00028,786,00025,350,00022,883,00019,886,00019,506,00016,305,000
  S&GA Expenses-3.7%11,524,00011,971,00012,134,00014,097,00017,828,00014,781,00015,874,00015,486,00013,709,00012,140,00011,428,00010,421,00010,920,0007,793,0007,705,0007,274,0006,388,0006,056,0005,466,0004,170,0003,696,000
  R&D Expenses-18.7%13,613,00016,738,00017,852,00016,573,00016,569,00014,957,00016,288,00017,098,00014,512,00013,617,00011,687,0009,496,0008,520,0007,193,0006,465,0006,390,0007,373,0005,303,0004,497,0005,245,0004,281,000
EBITDA Margin8.2%-1.32-1.44-1.48-1.52-1.61-1.38-1.13-0.93-0.69-0.62-0.54-0.48---------
Interest Expenses-40.0%9,00015,00039,00047,00047,00045,00050,00059,00059,00060,00065,000----2,000-204,000745,000184,000244,000
Income Taxes-82.1%5,00028,00036,00014,0008,00011,00014,0007,000-3,00012,0008,000-3,00018,0005,0004,00030,0004,0001,0002,0002,0002,000
Earnings Before Taxes8.6%-26,579,000-29,070,000-23,919,000-28,645,000-31,060,000-26,481,000-27,532,000-28,202,000-20,202,000-17,658,000-14,945,000-12,407,000-13,323,000-9,540,000-9,251,000-9,109,000-6,641,000-6,884,000-5,867,000-5,683,000-3,553,000
EBT Margin7.8%-1.47-1.60-1.64-1.66-1.74-1.48-1.22-1.01-0.76-0.69-0.61-0.55---------
Net Income8.6%-26,584,000-29,098,000-23,955,000-28,659,000-31,068,000-26,492,000-27,546,000-28,209,000-20,199,000-17,670,000-14,953,000-12,404,000-13,341,000-9,545,000-9,255,000-9,139,000-6,645,000-6,885,000-5,869,000-5,685,000-3,555,000
Net Income Margin7.8%-1.47-1.60-1.64-1.66-1.74-1.48-1.23-1.01-0.76-0.69-0.61-0.55---------
Free Cashflow3.5%-16,942,000-17,549,000-13,155,000-19,523,000-26,300,000-36,179,000-37,659,000-19,991,000-18,851,000-20,842,000-30,036,000-12,182,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-0.7%22522724927229331835838139740738339624524914615215716019242.00
  Current Assets-1.0%14714816118320022226029431832935437322122412013514014017630.00
    Cash Equivalents-21.1%57.0072.0097.0087.0089.0084.0087.0092.0010680.0070.0013769.0013325.0047.0055.0087.0016320.00
  Net PPE1.1%57.0057.0059.0061.0062.0061.0048.0031.0020.0018.0014.0011.0012.0013.0013.0013.0014.0015.0013.0011.00
Liabilities26.8%96.0075.0073.0079.0075.0075.0093.0094.0086.0081.0045.0047.0050.0045.0052.0053.0051.0048.0075.0059.00
  Current Liabilities45.4%47.0032.0029.0034.0033.0034.0042.0040.0031.0027.0034.0039.0041.0036.0043.0052.0050.0047.0056.0058.00
Shareholder's Equity-14.4%12915117619421824226528731032533934819520493.0099.00107111117-
  Retained Earnings-6.0%-468-442-413-389-360-329-302-275-247-226-209-194-181-168-158-149-140-133-127-115
  Additional Paid-In Capital0.8%5985945895835795735695635585525485433773722522492472452449.00
Shares Outstanding3.0%50.0049.0049.0047.0047.0046.0046.0045.0044.0044.0043.0042.00--------
Float---90,600---156---900---248---513-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations19.6%-13,418-16,681-10,414-15,745-16,762-14,765-27,349-11,357-15,274-17,880-25,931-11,743-2,532-16,124-15,354-8,6432,405-9,638-10,90266.003,203
  Share Based Compensation-2.7%3,3893,4823,4853,6955,7874,4154,4154,8164,0323,6893,6003,0573,4771,6901,8221,2491,2011,4021,646609393
Cashflow From Investing-35.2%-11,638-8,60519,54913,79321,85110,82623,021-3,16139,91129,669-47,105-82,544-63,1405,647-7,615-35.00-34,848-43,930-1,841-960-671
Cashflow From Financing3284.8%9,816290--511760-4205151,347-5066,010162,849941118,6831,321323471-22,686142,77714,38638.00

PSNL Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 73,481$ 65,047$ 85,494
Costs and expenses   
Cost of revenue55,27351,69753,837
Research and development64,77664,91249,312
Selling, general and administrative49,72663,96947,698
Lease impairment5,565  
Restructuring and other charges8,077  
Total costs and expenses183,417180,578150,847
Loss from operations(109,936)(115,531)(65,353)
Interest income5,9012,396367
Interest expense(110)(201)(184)
Other income (expense), net(4,068)61(42)
Loss before income taxes(108,213)(113,275)(65,212)
Provision for income taxes834014
Net loss$ (108,296)$ (113,315)$ (65,226)
Net loss per share, basic$ (2.25)$ (2.48)$ (1.49)
Net loss per share, diluted$ (2.25)$ (2.48)$ (1.49)
Weighted-average shares outstanding, basic48,175,20145,704,80543,886,730
Weighted-average shares outstanding, diluted48,175,20145,704,80543,886,730

PSNL Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 56,984$ 89,128
Short-term investments57,19578,530
Accounts receivable, net17,73016,642
Inventory and other deferred costs10,4748,591
Prepaid expenses and other current assets4,3616,808
Total current assets146,744199,699
Property and equipment, net57,36661,935
Operating lease right-of-use assets17,85226,480
Other long-term assets3,1374,586
Total assets225,099292,700
Current liabilities  
Accounts payable14,92012,854
Accrued and other current liabilities23,94119,013
Contract liabilities3,2881,264
Short-term warrant liability5,085 
Total current liabilities47,23433,131
Long-term operating lease liabilities38,32141,041
Long-term warrant liability4,942 
Other long-term liabilities5,161389
Total liabilities95,65874,561
Commitments and contingencies (Note 11)
Stockholders’ equity  
Common stock, $0.0001 par value - 200,000,000 shares authorized; 50,480,694 and 46,707,084 shares issued and outstanding, respectively55
Additional paid-in capital598,364579,456
Accumulated other comprehensive loss(222)(912)
Accumulated deficit(468,706)(360,410)
Total stockholders’ equity129,441218,139
Total liabilities and stockholders’ equity$ 225,099$ 292,700
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.
 CEO
 WEBSITEpersonalis.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES395

Personalis Inc Frequently Asked Questions


What is the ticker symbol for Personalis Inc? What does PSNL stand for in stocks?

PSNL is the stock ticker symbol of Personalis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Personalis Inc (PSNL)?

As of Mon Apr 15 2024, market cap of Personalis Inc is 63.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSNL stock?

You can check PSNL's fair value in chart for subscribers.

What is the fair value of PSNL stock?

You can check PSNL's fair value in chart for subscribers. The fair value of Personalis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Personalis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSNL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Personalis Inc a good stock to buy?

The fair value guage provides a quick view whether PSNL is over valued or under valued. Whether Personalis Inc is cheap or expensive depends on the assumptions which impact Personalis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSNL.

What is Personalis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, PSNL's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 0.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSNL PE ratio will change depending on the future growth rate expectations of investors.